Budget Saving Potential of Pegfilgrastim Biosimilar for the Treatment of Chemotherapy-Induced Febrile Neutropenia, in Italy

被引:0
|
作者
Berto, Patrizia [1 ]
Bellone, Marco [2 ]
Sabinot, Alice [2 ]
Pinto, Carmine [3 ]
Martino, Massimo [4 ]
Generali, Daniele [4 ]
Carriero, Pier Luigi [5 ]
Sanna, Maria Domenica [1 ]
机构
[1] Regulatory Pharma Net Srl, Pisa, Italy
[2] AdRes HE&OR, Turin, Italy
[3] AUSL IRCCS, Med Oncol Unit, Comprehens Canc Ctr, Reggio Emilia, Italy
[4] Univ Trieste, Cattinara Hosp, Dept Med Surg & Hlth Sci, Trieste, Italy
[5] Accord Healthcare Italy, Milan, Italy
关键词
Biosimilars; Budget Impact Analysis; Cost saving; Febrile neutropenia; Granulocyte colony stimulating factor (G-CSF); COLONY-STIMULATING FACTORS; CANCER-PATIENTS; BREAST-CANCER; ELDERLY-PATIENTS; DAILY FILGRASTIM; PRIMARY PROPHYLAXIS; CLINICAL-PRACTICE; G5; COUNTRIES; IMPACT; METAANALYSIS;
D O I
10.7175/fe.v23i1.1516
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
INTRODUCTION: Current Italian guidelines recommend prophylaxis with granulocyte colony-stimulating factors (G-CSFs) to reduce the risk of chemotherapy-induced febrile neutropenia (FN). The availability of G-CSF biosimilars represents an opportunity for savings in the Italian National Healthcare Service (NHS) delivery of care. OBJECTIVE: To assess the cost saving potential associated with the introduction of pegfilgrastim biosimilars to local formularies, compared to the current G-CSF standard practice in Italy. METHODS: A budget impact model was developed to compare the current standard practice of long-acting (LA) and shortacting (SA) G-CSFs use, with a titture scenario in which the market share of LA G-CSFs grows due to the more advantageous administration schedule and price of pegfilgrastim biosimilar. The analysis included G-CSF treatment schedules, drug acquisition costs and costs of patient management including hospitalization and ambulatory care. RESULTS: The introduction of pegfilgrastim biosimilar resulted in cumulative 3-year cost savings off. 59,650 and E 41,539 for FN prophylaxis in a potential cohort of 1000 patients with solid tumors and lymphomas, respectively. CONCLUSIONS: The results indicate that the introduction of pegfilgrastim biosimilar is potentially associated with substantial cost savings for the Italian healthcare system.
引用
收藏
页码:1 / 12
页数:12
相关论文
共 50 条
  • [1] RGB-02 (biosimilar pegfilgrastim) in the treatment of chemotherapy-induced neutropenia
    Santha, Dora
    Illes, Andras
    Aradi, Ildiko
    Horvat-Karajz, Karoly
    Kahan, Zsuzsanna
    FUTURE ONCOLOGY, 2019, 15 (18) : 2083 - 2092
  • [2] Cost-efficiency analyses for the US of biosimilar filgrastim-sndz, reference filgrastim, pegfilgrastim, and pegfilgrastim with on-body injector in the prophylaxis of chemotherapy-induced (febrile) neutropenia
    McBride, Ali
    Campbell, Kim
    Bikkina, Mohan
    MacDonald, Karen
    Abraham, Ivo
    Balu, Sanjeev
    JOURNAL OF MEDICAL ECONOMICS, 2017, 20 (10) : 1083 - 1093
  • [3] Role of biosimilar pegfilgrastim in the treatment of febrile neutropenia: A Mini Review
    Shahab, Shania
    Ahmad, S.
    INDIAN JOURNAL OF BIOCHEMISTRY & BIOPHYSICS, 2024, 61 (01) : 7 - 15
  • [4] Cost-effectiveness of pegfilgrastim versus filgrastim for prevention of chemotherapy-induced febrile neutropenia in patients with lymphoma: a systematic review
    Gebremariam, Girma Tekle
    Fentie, Atalay Mulu
    Beyene, Kebede
    Sander, Beate
    Gebretekle, Gebremedhin Beedemariam
    BMC HEALTH SERVICES RESEARCH, 2022, 22 (01)
  • [5] Pegfilgrastim for the prevention of chemotherapy-induced febrile neutropenia in patients with solid tumors
    Lambertini, Matteo
    Ferreira, Arlindo R.
    Del Mastro, Lucia
    Danesi, Romano
    Pronzato, Paolo
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2015, 15 (12) : 1799 - 1817
  • [6] Spotlight on Pegfilgrastim in Chemotherapy-Induced Neutropenia
    James E. Frampton
    Gillian M. Keating
    BioDrugs, 2005, 19 : 405 - 407
  • [7] Economic burden of chemotherapy-induced febrile neutropenia in patients with lymphoma: A systematic review
    Wang, Xiao Jun
    Lopez, Shaun Eric
    Chan, Alexandre
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2015, 94 (02) : 201 - 212
  • [8] Pegfilgrastim-Apgf (Nyvepria): Biosimilar USFDA Approval for the Treatment of Chemotherapy-induced Febrile Neutropenia and Current Updates on Clinical Trials
    Ali, Faraat
    Sharma, Kamna
    Ali, Asad
    CURRENT DRUG TARGETS, 2022, 23 (09) : 924 - 932
  • [9] Risk of chemotherapy-induced febrile neutropenia by day of pegfilgrastim prophylaxis in US clinical practice from 2010 to 2015
    Weycker, Derek
    Bensink, Mark
    Lonshteyn, Alexander
    Doroff, Robin
    Chandler, David
    CURRENT MEDICAL RESEARCH AND OPINION, 2017, 33 (12) : 2107 - 2113
  • [10] Prevention and Treatment of Chemotherapy-Induced Febrile Neutropenia in Adults
    Park, Hye Min
    Pom, Boramey
    Farina, Kyle A.
    Rattu, Mohammad A.
    US PHARMACIST, 2023, 48 (04)